Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and cancer and leukemia group B study

Journal of Clinical Oncology

Volumn 16, Issue 4, 1998, Pages 1287-1293

  Nichols, Craig R ^a   Catalano, Paul J ^b   Crawford, E David ^b   Vogelzang, Nicholas J ^b   Einhorn, Lawrence H ^b   Loehrer, Patrick J ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0031950313     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.4.1287     Document Type: Article

References (15)

1. Einhorn L: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8:1777-1781, 1990
2. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
3. Bajorin D, Sarosdy M, Pfister D, et al: A randomized trial of etoposide + cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
4. Nichols C, Williams S, Loehrer P, et al: Randomized study of cisplatin dose intensity in advanced germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991
5. Chevreau C, Droz J, Pico J, et al: Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk non-seminomatous germ cell tumors. Preliminary results of a French randomized trial. Eur Urol 23:213-217, 1993
6. Kaye S, Mead G, Fossa S, et al: An MRC/EORTC randomized trial in poor prognosis metastatic teratoma comparing BEP to BOP-VIP. Proc Am Soc Clin Oncol 14:246, 1995 (abstr)
7. Scheulen M, Niederle N, Hoffken K, et al: Ifosfamide/Mesna alone or in combination with etoposide: Salvage therapy for patients with metastasized nonseminomatous testicular cancer. Proc Am Soc Clin Oncol 4:97, 1985 (abstr)
8. Wheeler B, Loehrer P, Williams S, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
9. Einhorn L, Weathers T, Loehrer P, et al: Second line chemotherapy with vinblastine, ifosfamide, and cisplatin after initial chemotherapy with cisplatin, VP-16 and bleomycin (PVP-16B) in disseminated germ cell tumors (GCT). Proc Am Soc Clin Oncol 11:196, 1992 (abstr)
10. Motzer R, Cooper K, Geller N, et al: The role of cisplatin + ifosfamide based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481, 1992
11. Birch R, Wiliams S, Cone A, et al: Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400-407, 1986
12. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
13. Droz J, Kramer A, Ghosn M, et al: Prognostic factors in advanced nonseminomatous testicular cancer: A multivariate logistic regression analysis. Cancer 62:564-568, 1988
14. Stoter G, Sleijfer D, Schornagel J, et al: BEP versus VIP in intermediate risk patients with disseminated non-seminomatous testicular cancer (NSTC). Proc Am Soc Clin Oncol 12:232, 1993 (abstr)
15. Group IGCCC: International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594-603, 1997